Immunodiagnostics group Oncimmune Holdings said on Thursday that its EarlyCDT lung test had been approved by the Ministry of Health for Aragon in Spain and is now being rolled out at the Miguel Servet University Hospital in Zaragoza.
Oncimmune’s CDT early lung blood test is being adopted by the University Hospital’s Department of Thoracic Surgery for use in single pulmonary nodules.
The AIM-listed group noted that the approval follows the publication of a positive assessment and report by the Aragonese Health System Evaluation Committee, which found that it had met the required criteria in terms of efficacy and safety.
Oncimmune stressed that the approval also comes after its EarlyCDT Lung asset was approved by the Galician Health Service for use in the Spanish Public Health Service.
chief executive dr Adam M. Hill said, “We are pleased with the progress made by our Spanish distributor Sabartech in the wider adoption of the EarlyCDT blood test in the Spanish public health system.
“The progress made in Spain reflects the positive engagement we are seeing with several NHS Clinical Commissioning Groups and Cancer Alliances in the UK. Overall, this is an encouraging development for continued adoption of the EarlyCDT lung blood test in national health systems worldwide.”
As of 1145 GMT, Oncimmune shares are up 3.25% at 143.0 pence.